小川 啓恭 おがわ ひろやす 先生

来歴等

略歴

1978年 大阪大学医学部 卒業
1987年 大阪大学 医学博士取得
1987年 大阪大学第三内科 助手
1995年 大阪大学第三内科 講師
1998年 大阪大学第三内科（分子病態内科） 准教授
2005年 兵庫医科大学血液内科 教授
2018年 大阪暁明館病院 血液内科部長

論文

• Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR. Bone Marrow Transplant, 53(4): 478-482, 2018. doi: 10.1038/s41409-017-0028-x

  Ogawa H, Ikegame K, Daimon T, Uchida N, Fukuda T, Kakihana K, Eto T, Ozawa Y, Kanamori H, Hidaka M, Iwato Y, Ichinohe T, Takanashi M, Atsuta Y, Kanda Y.

• A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning. European Journal of Haematology, 100(4): 335-343, 2018. doi: 10.1111/ejh

  Okada M, Tasaka T, Ikegame K, Aotsuka N, Kobayashi T, Najima Y, Matsuhashi Y, Wada H, Tokunaga H, Masuda S, Utsu Y, Yoshihara S, Kaida K, Daimon T, Ogawa H.

• Spousal hematopoietic stem cell transplantation. Int J Hematol, 105(5): 646-657, 2017. 10.1007/s12185-016-2168-y

  Ikegame K, Kaida K, Yoshihara S, Yoshihara K, Ishii S, Inoue T, Okada M, Tamaki H, Soma T, Kusunoki Y, Kojima H, Saji H, Ogawa H.

• Host Foxp3+CD4+ regulatory T cells act as a negative regulator of dendritic cells in the peritransplantation period. Journal of Immunology, 196: 469-483, 2016. doi: 10.4049/jimmunol.1402950.

  Inoue T, Ikegame K, Kaida K, Okada M, Yoshihara S, Tamaki H, Fujimori Y, Soma T, Ogawa H.

• Unmanipulated haploidentical RIST using fludarabine, busulfan, low- dose ATG and steroid for patients in non-CR or at high risk of relapse: a prospective multicenter phase I/II study in Japan. Biology of Blood and Marrow Transplantation, 21: 1495-1505, 2015.

  Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, Ueda Y, Kaida K, Ishii S, Taniguchi K, Okada M, Tamaki H, Okumura H, Kaya H, Kurokawa T, Kodera Y, Taniguchi S, Kanda Y, Ogawa H.

• Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced intensity conditioning. International Journal of Hematology, 99: 463-470, 2014.

  *Kaida K, *Ikegame K, Ikemoto J, Murata R, Irie R, Yoshihara S, Ishii S, Okada M, Inoue T, Tamaki H, Soma T, Fujimori Y, Kai S, Ogawa H.

• Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant, 48: 859-864, 2013.

  Fujioka T, Tamaki H, Ikegame K, Yoshihara S, Taniguchi K, Kaida K, Kato R, Inoue T, Nakata J, Ishii S, Soma T, Okada M, Ogawa H.

• Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients. International Journal of Hematology, 96; 101-108, 2012.

  Ikegame K, Kaida K, Yoshihara S, Fujiwara M, Taniguchi K, Kato R, Inoue T, Fujioka T, Tamaki H, Okada M, Soma T, Kamikonya N, Saji H, Hirota S, Ogawa H.

• Intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning treatment: a phase I study. Biology of Blood and Marrow Transplantation, 18; 633-639, 2012.

  Okada M, Yoshihara S, Taniguchi K, Kaida K, Ikegame K, Kato R, Tamaki H, Inoue T, Soma T, Kai S, Kato S, Ogawa H.

• Allogeneic stem cell transplantation as treatment for heavily-treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation. Experimental Hematology, 39; 880-890, 2011.

  Ikegame K, Yoshihara S, Taniguchi Y, Kaida K, Inoue T, Okada M, Taniguchi K, Hasei H, Tamaki H, Fujioka T, Kato R, Soma T, Ogawa H.

• Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells. International Journal of Hematology, 91: 485-497, 2010.

  Satake A, Inoue T, Kubo S, Taniguchi Y, Imado T, Fujioka T, Horiuchi M, Xu Y, Ikegame K, Yoshihara S, Kaida K, Tamaki H, Okada M, Okamura H, Ogawa H.

• Recovery from established graft-versus-host disease achieved by bone marrow transplantation from a third-party allogeneic donor. Experimental Hematology, 36:1216-1225, 2008.

  Taniguchi Y, Yoshihara S, Hoshida Y, Inoue T, Fujioka T, Ikegame K, Kawakami M, Masuda T, Aozasa K, Kawase I, Ogawa H.

• Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Experimental Hematology, 36: 1-8, 2008.

  Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, Tamaki H, Inoue T, Hasei H, Iiboshi Y, Tazuke Y, Kawakami M, Kim EH, Soma T, Inoue T and Kawase I.

• A Novel Direct Competitive Repopulation Assay For Human Hematopoietic Stem Cells Using NOD/SCID Mice. Cytotherapy, 8: 390-398, 2006.

  Tatekawa T, Ogawa H, Kawakami M, Oka Y, Yasukawa K, Sugiyama H, Kawase I, and Soma T.

• Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 12: 1073-1084, 2006.

  Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.

• HLA-haploidentical nonmyeloablative stem cell transplantation: Induction to tolerance without passing through mixed chimerism. Clinical and Laboratory Haematology, 27: 1-3, 2005.

  Ikegame K, Kawakami M, Yamagami T, Maeda H, Onishi K, Taniguchi Y, Fujioka T, Masuda T, Kawase I, Ogawa H.

• Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation. Transplantation, 78: 488-489, 2004.

  Ogawa H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Yoshihara S, Tatekawa T, Oji Y, Oka Y, Kawase I.

• Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large–scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation. International Journal of Hematology, 79: 495-500, 2004.

  Ogawa H, Ikegame K, Kawakami M, Takahashi S, Sakamaki H, Karasuno T, Sao H, Kodera Y, Hirabayashi N, Okamoto S, Harada M, Iwato K, Maruta A, Tanimoto M, Kawa K.

• Allogeneic bone marrow transplantation with non-T-cell-depleted marrow from two HLA-antigen-mismatched related donors. Haematologica, 89: 373-375, 2004. 20. Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N, Ikegame K, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Osumi K, Soma T, Oji Y, Oka Y, Kawase I, Sugiyama H, and Ogawa H. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms' tumor gene (WT1). International Journal of Hematology, 78: 349-356, 2003.

  Ogawa H, Ikegame K, Kawakami M, Taniguchi Y, Oka Y, and Kawase I.

• Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms' tumor gene (WT1). International Journal of Hematology, 78: 349-356, 2003

  Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N, Ikegame K, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Osumi K, Soma T, Oji Y, Oka Y, Kawase I, Sugiyama H, and Ogawa H.

• Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia, 17: 2052-2054, 2003.

  Tamaki H, Ikegame K, Kawakami M, Fujioka T, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Kawase I, and Ogawa H.

• Treatment of severe life-threatening graft-versus-host disease by autologous peripheral blood stem cell transplantation using a nonmyeloablative preconditioning regimen. Haematologica, 88: ELT06, 2003.

  Taniguchi Y, Ikegame K, Yoshihara S, Sugiyama H, Kawase I, and Ogawa H.

• The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model. Transplant Immunology, 11: 187-195, 2003.

  Fujioka T, Taniguchi Y, Masuda T, Nishida S, Ikegame K, Kawakami M, Tsuboi A, Hosen N, Murakami M, Oji Y, Oka Y, Sugiyama H, Kawase I, and Ogawa H.

• The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood, 101: 1698-1704, 2003.

  Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Oji Y, Oka Y and Sugiyama H.

• The combination of tacrolimus, methotrexate, and methylprednisolone completely prevents acute graft-versus-host disease(GVHD) but not chronic GVHD in unrelated bone marrow transplantation. Transplantation, 74: 236-243, 2002.

  Ogawa H, Soma T, Hosen N, Tatekawa T, Tsuboi A, Oji Y, Tamaki H, Kawakami M, Ikegame K, Murakami M, Fujioka T, Kim EH, Oka Y, Sugiyama H.

• Wilms tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood, 91: 2969-2976, 1998.

  Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Akiyama T, Kishimoto T and Sugiyama H.

• A high incidence of chemotherapy-induced acral erythema (CAE) in female patients with non-Hodgkin’s lymphoma who were treated with VACOP-B regimen. Leukemia and Lymphoma, 29: 171-177, 1998.

  Ogawa H, Sugiyama H, Tani Y, Soma T, Yamagami T, Tatekawa T, Oji Y, Kubota T, Kimura T, Inoue K, Nakagawa M, Sasaki K, Matsunashi T, Miyake S and Kishimoto T.

• Isolation of cDNA clone encoding a novel membrane protein expressed in lymphocytes. FEBS letters, 355: 30-34, 1994.

  Shimizu Y, Ogawa H, Oka Y, Mizuno R, Sakoda S, Kishimoto T and Sugiyama H.

• No correlation between location of bcr breakpoints and clinical states in Ph1-positive CML patients. Leukemia, 3: 492-496, 1989.

  Ogawa H, Sugiyama H, Soma T, Masaoka T and Kishimoto S.

• Rearrangement of immunoglobulin heavy chain genes and T3 expression in the absence of rearrangement of T-cell receptor -chain gene in a patient with T-cell malignant lymphoma. Leukemia Research, 10: 1369-1375, 1986.

  Ogawa H, Sugiyama H, Oka Y, Maeda T, Komori T, Tani Y, Miyake S, Soma T, Maekura R, Yutani C, Masaoka T and Kishimoto S.

著書

• 【分担執筆】岡田昌也、小川啓恭、骨髄内臍帯血ミニ移植の臨床開発、Annual Review 血液 2013 中外医学社, 2013

• 【分担執筆】池亀和博、小川啓恭、GVH反応とGVL反応におけるT細胞の異なった役割、臨床免疫・アレルギー科、56: 202-205, 2011

• 【分担執筆】池亀和博、小川啓恭、HLA半合致移植、血液疾患　最新の治療 2011-2013、316-321, 南江堂

• 【分担執筆】吉原　哲、小川啓恭、同種造血幹細胞移植における拒絶・移植片対宿主病の制御薬とその適応—抗ヒト胸腺細胞免疫グロブリン(ATG)、血液フロンティア、18: 43-51, 2008.

• 【分担執筆】海田勝仁、小川啓恭、骨髄移植後に髄外再発を認めたMyeloid NK cell precursor acute leukemia. Front Wave in Hematology, 22: 2-3, 2007

• 【分担執筆】池亀和博、小川啓恭、血縁HLA不適合移植、血液・腫瘍科、54: 216-226, 2007

• 【分担執筆】池亀和博、小川啓恭、血縁者間HLA半合致ミニ移植、臨床血液、47: 589-598, 2006

• 【分担執筆】吉原　哲、小川啓恭、血液疾患治療時の輸血、顆粒球輸血・DLIを中心に、血液フロンティア、15: 69-76, 2005

• 【分担執筆】小川啓恭、急性白血病に対する同種造血幹細胞移植におけるWT1測定の応用、臨床血液、45: 501-508, 2004

• 【分担執筆】金　義浩、小川啓恭、治療抵抗性悪性腫瘍に対するHLA不適合移植の有用性、Molecular Medicine、40: 1480-1485, 2003

• 【分担執筆】小川啓恭、HLA不一致ドナーからのミニ移植、日本臨床、61: 1549-1554, 2003

• 【分担執筆】小川啓恭、HLA不一致移植とその倫理、内科、92: 494-498, 2003

• 【分担執筆】玉置広哉、小川啓恭、白血病の微少残存病変の評価、日本内科学会雑誌、92: 956-962, 2003

• 【分担執筆】小川啓恭、治療選択におけるMRDの有用性はどこまで明らかにされたのか？EBM 血液疾患の治療、中外医学社、187-196, 2002

• 【分担執筆】小川啓恭、微小残存白血病細胞、日本臨床、59: 2348-2352, 2001

• 【分担執筆】玉置広哉、小川啓恭、杉山治夫、微小残存病変の検出と白血病の治療戦略、治療学、35: 65-69, 2001

• 【分担執筆】小川啓恭、微小残存病変の評価、綜合臨床、49: 2586-2592, 2000

• 【分担執筆】川上　学、小川啓恭、杉山治夫、白血病腫瘍マーカーによる予後の予測は可能か、臨床成人病、30: 469-473, 2000

• 【分担執筆】小川啓恭、微小残存病変モニタリングによる白血病治療—微小残存病変の診断と治療の実際、臨床成人病、30: 527-533, 2000

• 【分担執筆】小川啓恭、微小残存病変を指標としたdonor leukocyte transfusion (DLT)の適応、血液フロンティア、9: 517-524, 1999